Skip to main content
. 2017 Nov 20;12(11):e0187804. doi: 10.1371/journal.pone.0187804

Fig 4. The effect of pancreatin on the appetite loss was evaluated in CHF patients with FE-1 levels <200 μg/g stool and SNAQ < 14.

Fig 4

A. SNAQ score; B. Albumin; C. Pro-albumin. Compared with placebo group, pancreatin could significantly improve the SNAQ score in treatment group as well as albumin and pro-albumin. The data are expressed as means ± SD. *p<0.05.